source
- Spyre Therapeutics reports SPY072 fails psoriatic arthritis trial as Ideaya halts eye cancer studySpyre Therapeutics announced that its long‑acting anti‑TL1A candidate, SPY072, did not meet the primary endpoints in a psoriatic arthritis trial. The result adds to recent setbacks for Spyre in ot…
- Sanofi halts development of Nurix's STAT6 degrader programSanofi announced it will stop work on an experimental drug that targets STAT6, a protein involved in immune signaling. The compound, known as SAR448272 and developed in partnership with Nurix, was…